Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis

Our aim is to evaluate the safety and efficacy of two treatment strategies, hyperthermic intraperitoneal chemotherapy (HIPEC) plus simultaneous versus staged cytoreductive surgery (CRS) in patients with occult peritoneal metastasis of gastric cancer (GC).

[1]  Jie He,et al.  Annual report on status of cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[2]  L. Graziosi,et al.  Role of CRS plus HIPEC in gastric cancer peritoneal carcinomatosis , 2015, Journal of surgical oncology.

[3]  John E. Mullinax,et al.  Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial , 2014, Journal of surgical oncology.

[4]  S. Barni,et al.  Gastric cancer: toward a cisplatin-free disease? , 2014, Journal of gastrointestinal oncology.

[5]  J. Lortet-Tieulent,et al.  Expansion of cancer registration in China. , 2014, Annals of translational medicine.

[6]  M. Blanco-Calvo,et al.  Clinical and molecular aspects of miR-200 family in gastric cancer , 2014 .

[7]  I. Maetani.  Self-expandable metallic stent placement for palliation in gastric outlet obstruction. , 2014, Annals of palliative medicine.

[8]  C. Willett,et al.  Intraoperative radiotherapy in the treatment of gastrointestinal malignancies , 2014 .

[9]  Jie He,et al.  Annual report on status of cancer in China, 2010. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  S. Katz,et al.  Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. , 2013, Hepatobiliary surgery and nutrition.

[11]  P. Sugarbaker.  Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy , 2013 .

[12]  Yasuhide Yamada,et al.  Molecular therapy for gastric cancer. , 2013, Chinese clinical oncology.

[13]  J. Ji,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination , 2013, Tumor Biology.

[14]  A. Rademaker,et al.  Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant. , 2012, Chinese clinical oncology.

[15]  M. Choi,et al.  Long‐term results and prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology , 2012, Journal of surgical oncology.

[16]  Sangho Jeong,et al.  A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer , 2012, Investigational New Drugs.

[17]  Coral L. Atoria,et al.  Staging laparoscopy in the management of gastric cancer: a population-based analysis. , 2011, Journal of the American College of Surgeons.

[18]  S. Tatebe,et al.  Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis , 2011, Journal of surgical oncology.

[19]  T. Yoshikawa,et al.  Indications for Staging Laparoscopy in Clinical T4M0 Gastric Cancer , 2011, World Journal of Surgery.

[20]  Yan Li,et al.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial , 2011, Annals of Surgical Oncology.

[21]  P. Sugarbaker.  Surgical responsibilities in the management of peritoneal carcinomatosis , 2010, Journal of surgical oncology.

[22]  K. Muro,et al.  Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Cotte,et al.  Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy , 2010, Annals of Surgical Oncology.

[24]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[26]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Ming-ming Nie,et al.  [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. , 2005, Ai zheng = Aizheng = Chinese journal of cancer.

[28]  T. Kawamura,et al.  Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion , 2005, The British journal of surgery.

[29]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[30]  T. Hickish,et al.  Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Fukushima,et al.  Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. , 2001, Anticancer research.

[32]  H. Takamizawa,et al.  Intraperitoneal Hyperthermic Perfusion Combined with Surgery Effective for Gastric Cancer Patients with Peritoneal Seeding , 1988, Annals of surgery.

[33]  O. Khan,et al.  In patients with radiologically-staged resectable oesophago-gastric junctional tumours, is diagnostic laparoscopy useful as an additional staging procedure? , 2012, International journal of surgery.

[34]  PhD Kay Washington MD.  7th Edition of the AJCC Cancer Staging Manual: Stomach , 2010, Annals of Surgical Oncology.

[35]  C. Compton,et al.  Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. , 2010, Archives of pathology & laboratory medicine.

[36]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[37]  M. Brennan,et al.  Selection of patients with gastric adenocarcinoma for laparoscopic staging. , 2006, American journal of surgery.

[38]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .